BNP-32
BNP-32 Uses, Dosage, Side Effects, Food Interaction and all others data.
BNP-32 is a medication used to treat acutely decompensated congestive heart failure with dyspnea at rest or with minimal exertion (such as talk, eating or bathing). BNP-32 is a 32 amino acid recombinant human B-type natriuretic peptide.
BNP-32 works by facilitating cardiovascular homeostasis through the negative regulation of the renin-angiotensin-aldosterone system. This regulation will in order stimulate cyclic guanosine monophosphate and smooth muscle cell relaxation. In simpler terms, it promotes vasodilation, natriuresis, and diuresis.
| Trade Name | BNP-32 |
| Availability | Discontinued |
| Generic | Nesiritide |
| Nesiritide Other Names | BNP, BNP-32, Brain natriuretic peptide 32, Nesiritide, Nesiritide recombinant |
| Related Drugs | amlodipine, lisinopril, metoprolol, furosemide, carvedilol, spironolactone |
| Type | |
| Weight | 3464.0 Da |
| Groups | Approved, Investigational |
| Therapeutic Class | |
| Manufacturer | |
| Available Country | |
| Last Updated: | September 19, 2023 at 7:00 am |
Uses
BNP-32 is a recombinant natriuretic peptide used for the treatment of patients with acutely decompensated congestive heart failure who have dyspnea at rest or with minimal activity.
For the intravenous treatment of patients with acutely decompensated congestive heart failure who have dyspnea at rest or with minimal activity.
BNP-32 is also used to associated treatment for these conditions: Acute Decompensated Heart Failure (ADHF)
How BNP-32 works
Human BNP binds to the particulate guanylate cyclase receptor of vascular smooth muscle and endothelial cells, leading to increased intracellular concentrations of guanosine 3'5'-cyclic monophosphate (cGMP) and smooth muscle cell relaxation. Cyclic GMP serves as a second messenger to dilate veins and arteries. BNP-32 has been shown to relax isolated human arterial and venous tissue preparations that were precontracted with either endothelin-1 or the alpha-adrenergic agonist, phenylephrine. In human studies, nesiritide produced dose-dependent reductions in pulmonary capillary wedge pressure (PCWP) and systemic arterial pressure in patients with heart failure. In animals, nesiritide had no effects on cardiac contractility or on measures of cardiac electrophysiology such as atrial and ventricular effective refractory times or atrioventricular node conduction. Naturally occurring atrial natriuretic peptide (ANP), a related peptide, increases vascular permeability in animals and humans and may reduce intravascular volume. The effect of nesiritide on vascular permeability has not been studied.
Toxicity
No data are available with respect to overdosage in humans. The expected reaction would be excessive hypotension, which should be treated with drug discontinuation or reduction and appropriate measures.
BNP-32 Drug Interaction
Unknown: amoxicillin / clavulanate, amoxicillin / clavulanate, glucose, glucose, heparin, heparin, sodium iodide, sodium iodide, carbonyl iron, carbonyl iron, ferrous sulfate, ferrous sulfate, niacin, niacin, acetaminophen / hydrocodone, acetaminophen / hydrocodone, acetaminophen, acetaminophen, oxycodone, oxycodone
BNP-32 Disease Interaction
Volume of Distribution
- 0.19 L/kg
Elimination Route
Administration of nesiritide exhibits biphasic disposition from the plasma.
Half Life
Approximately 18 minutes
Clearance
- 9.2 mL/min/k [patients with congestive heart failure receiving IV infusion]
Elimination Route
Human BNP is cleared from the circulation via the following three independent mechanisms, in order of decreasing importance: 1) binding to cell surface clearance receptors with subsequent cellular internalization and lysosomal proteolysis; 2) proteolytic cleavage of the peptide by endopeptidases, such as neutral endopeptidase, which are present on the vascular lumenal surface; and 3) renal filtration.
Innovators Monograph
You find simplified version here BNP-32
